Download 10th International Congress on Peritoneal Surface Malignancies

10th International Congress on Peritoneal Surface Malignancies
November 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC
Course Director:
Paul H. Sugarbaker, MD, FACS, FRCS
MedStar Washington Hospital Center
Washington, DC
www.psogi2016.com
Course Description
In the past decade, the treatment of peritoneal metastases has
gained interest from oncologic communities around the world.
During the 1990’s, the first pioneering centers began treating
patients with hyperthermic intraperitoneal chemotherapy (HIPEC).
Prior to HIPEC, patients were treated with palliative support and only
guaranteed a few months to live. Today, if a patient with peritoneal
metastases is provided with proper treatment, the survival
increases to an average of several years and improved outcomes
are reported every day. The mission of the 10th International
Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to
provide clinical and scientific information on peritoneal surface
malignancies and to create awareness regarding innovative
treatments that will improve the quality of life for patients.
This two and a half day conference is carefully balanced to cover
the wide range of topics on peritoneal metastases. It will feature
keynote lectures, didactic sessions, debates, meet the professor
sessions with case presentations interspersed where appropriate.
Extended discussions with elite panels and extensive audience
participation is encouraged at this meeting. Individual paper
sessions and abstract poster presentations will also be included
in the meeting. Additionally, the program will include two
satellite programs on Saturday focusing on peritoneal metastases
imaging and pharmacology of chemotherapy treatments.
Congress at a Glance
WEDNESDAY, NOVEMBER 16
6:00 PM
Welcome Reception
page 6
THURSDAY, NOVEMBER 17
8:30 AM – 10:30 AM
Session I: Colorectal Cancer
page 6
11:00 AM – 1:00 PM
Session II: Ovarian Cancer
page 7
2:00 PM – 4:00 PM
Session III: Lecture/Debate
page 7
4:30 PM – 5:30 PM
Session IV: Debate/Cases
page 7
6:00 PM
Networking Welcome Reception
page 7
FRIDAY, NOVEMBER 18
6:30 AM – 8:00 AM
Session V: Meet the Professor Breakfast Sessions
page 8
8:15 AM – 9:30 AM
Session VI: Gastric Cancer
page 10
9:30 AM – 10:30 AM
Session VII: Registries
page 10
11:00 AM – 1:00 PM
Session VIII: Abstracts/Cases
page 11
2:00 PM – 4:00 PM
Session IX: Lecture/Debate/Cases
page 11
4:30 PM – 6:30 PM
Session X: Lecture/Debate/Cases
page 11
7:30 PM
Congress Banquet with Historical Video
page 11
SATURDAY, NOVEMBER 19
6:30 AM – 8:00 AM
Session XI: Meet the Professor Breakfast Sessions
page 9
8:15 AM – 10:30 AM
Session XII: New Technologies
page 12
11:00 AM – 1:00 PM
Session XIII: The Future
page 12
1:30 PM – 7:00 PM
Post-Conference Satellite Symposium Option 1
page 13
1:30 PM – 7:00 PM
Post-Conference Satellite Symposium Option 2
page 14
2
Course Information
learning objectives
cme accreditation
•
Utilize available data to determine optimal treatment options including
cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy
(HIPEC) for patients with peritoneal metastases (colorectal, gastric cancer,
ovarian cancer, appendiceal cancer, peritoneal mesothelioma)
•
Identify quantitative prognostic indicators to select patients who will most
likely benefit from cytoreductive surgery with HIPEC
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of MedStar Georgetown University
Hospital and MedStar Washington Hospital Center. MedStar Georgetown
University Hospital is accredited by the ACCME to provide continuing medical
education for physicians.
•
Optimize patient care by discussing the use of the appropriate clinical
pathways, patient protocols, and surgical procedures
•
Evaluate the potential efficacy of drugs for use in intraperitoneal or
intravenous administrations in the treatment of peritoneal metastases with
special emphasis on chemotherapy treatments used in the operating room
•
Discuss patient selection, surgical technique and management of
standardized HIPEC regiments resulting in improved patient outcomes
•
Distinguish patients at risk for carcinomatosis during early phases
target audience
This conference is intended for surgical and medical oncologists, surgical
oncology nurses, surgical technicians, perfusionists, gastroenterologists,
gynecologists, pharmacologists, pathologists, advanced practice clinicians. and
other healthcare professionals interested in peritoneal surface oncology.
credit designation
MedStar Georgetown University Hospital designates this live activity for a
maximum of 26 AMA PRA Category 1 Credits™. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
For Nurses
For the purpose of recertification, the American Nurses Credentialing Center
(ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited
by the ACCME. Nurses who attend a Category 1 CME certified activity can
complete the continuing education hours section of the ANCC Professional
Development Record in order to document the courses attended and the hours
obtained.
3
Faculty
course directors
Brendan J. Moran, MCh, FRCS, FRCSI
The North Hampshire Hospitals
Basingstoke, UNITED KINGDOM
H. Richard Alexander Jr., MD
University of Maryland Medical Center
Baltimore, MD, USA
Peter H. Cashin, MD, PhD
Uppsala University
Uppsala, SWEDEN
David Morris, MD
St. George Hospital
Kogarah, AUSTRALIA
Suzanne Alves, CNS
Peritoneal Malignancy Institute
Basingstoke, UNITED KINGDOM
Tom Cecil, BM, DM
Hampshire Hospitals
Basingstoke, UNITED KINGDOM
scientific organizing
committee
Pompiliu Piso, MD, PhD
Hospital Barmherzige Brueder
Regensburg, GERMANY
Luca Ansaloni, MD
Papa Giovanni XXIII Hospital
Bergamo, ITALY
Wim Ceelen, MD, PhD
Ghent University
Ghent, BELGIUM
David L. Bartlett, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA
Beate S. Rau, MD, PhD
Charité Campus Mitte University Hospital
Berlin, GERMANY
Alvaro Arjona-Sanchez, MD, PhD
Hospital U. Reina Sofia, Cordoba
Cordoba, SPAIN
John K. Chan, MD
Palo Alto Medical Foundation
San Francisco, CA, USA
Marcello Deraco, MD
Fondazione IRCCS - Istituto Nazionale dei
Tumori Milan, ITALY
Vic Verwaal, MD
Aarhus University Hospital
Aarhus, DENMARK
Naoual Bakrin, MD, PhD
Le Centre Hospitalier Lyon Sud
Lyon, FRANCE
Dennis S. Chi, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA
Yutaka Yonemura, MD, PhD
Kishiwada Tokushukai Hospital
Osaka, JAPAN
Dario Baratti, MD
Fondazione IRCCS - Istituto Nazionale dei
Tumori Milan, ITALY
Jean-Marc Classe, MD, PhD
Institut de Cancérologie de l’Ouest
Saint-Herblain
Nantes, FRANCE
faculty
Joel M. Baumgartner, MD, MAS, FACS
University of California, San Diego
San Diego, CA, USA
Eelco de Bree, MD, PhD
University Hospital Heraklion
Heraklion, GREECE
Lana Bijelic, MD
INOVA Health System
Falls Church, VA, USA
Ignace H. de Hingh, MD, PhD
Catharina Cancer Institute
Eindhoven, THE NETHERLANDS
Gina Brown, MD, FRCR
Royal Marsden NHS Foundation Trust
London, UNITED KINGDOM
Clarisse Dromain, MD, PhD
Institute Gustave Roussy
Paris, FRANCE
Paul H. Sugarbaker, MD, FACS, FRCS
MedStar Washington Hospital Center
Washington, DC, USA
Olivier Glehen, MD, PhD
Hospitalier Lyon Sud
Lyon, FRANCE
Diane Goere, MD, PhD
Institute Gustave Roussy
Paris, FRANCE
Santiago Gonzalez-Moreno, MD, PhD
MD Anderson Cancer Center Madrid
Madrid, SPAIN
Yan Li, MD, PhD
Beijing Shijitan Hospital
Beijing, CHINA
Nita Ahuja, MD
Johns Hopkins University
Baltimore, MD, USA
David S. Alberts, MD
University of Arizona Cancer Center
Tucson, AZ, USA
4
Jesus Esquivel, MD
Cancer Treatment Centers of America
Philadelphia, PA, USA
Joji Kitayama, MD
Jichi Medical University
Tokyo, JAPAN
Anna Fagotti, MD, PhD
Agostino Gemelli University
Rome, ITALY
Shigeki Kusamura, MD, PhD
Fondazione IRCCS - Istituto Nazionale dei
Tumori Milan, ITALY
Francois-Noel Gilly, MD, PhD
Hospices Civils de Lyon
Lyon, FRANCE
Evgenia A. Halkia, MD
Athens General Clinic
Athens, GREECE
Nader N. Hanna, MD
University of Maryland School of Medicine
Baltimore, MD, USA
Richard A. Hoefer Jr., DO
Sentara Surgery Specialists
Newport News, VA, USA
Charles Honore, MD, PhD
Institute Gustave Roussy
Paris, FRANCE
Marybeth S. Hughes, MD, FACS
National Cancer Institute
Bethesda, MD, USA
James S. Jelinek, MD
MedStar Washington Hospital Center
Washington, DC, USA
Helen M. Kennedy, RN, STN
St. George Hospital
Sydney, AUSTRALIA
Marc Pocard, MD, PhD
Lariboisière Hospital
St. Louis Hospital
Paris, FRANCE
Francois Quenet, MD
Institut Du Cancer De Montpellier
Montpellier, FRANCE
Kiran K. Turaga, MD, MPH
University of Chicago
Chicago, IL, USA
Kurt Van der Speeten, MD, PhD
Ziekenhuis Oost-Limburg
Hasselt, BELGIUM
Laura A. Lambert, MD
University of Massachusetts Medical School
Worcester, MA, USA
Steven A. Rosenberg, MD, PhD
National Cancer Institute
Bethesda, MD, USA
Willemien van Driel, MD, PhD
Netherlands Cancer Institute- Antoni Van
Leeuwenhoek
Amsterdam, THE NETHERLANDS
Edward A. Levine, MD
Wake Forest University
Winston-Salem, NC, USA
Pascal Rousset, MD, PhD
Centre Hospitalier Lyon Sud
Lyon, FRANCE
Stephanie L. Wethington, MD
MedStar Washington Hospital Center
Washington, DC, USA
Gabriel Liberale, MD
Institut Jules Bordet
Brussels, BELGIUM
David P. Ryan, MD
Massachusetts General Hospital
Boston, MA, USA
Frans A.N. Zoetmulder, MD, PhD
Zomba Central Hospital
Zomba, MALAWI
Faheez Mohamed, MD
Peritoneal Malignancy Institute
Basingstoke, UNITED KINGDOM
Paolo Sammartino, MD, PhD
Sapienza University of Rome
Rome, ITALY
Samantha A. Moritz, PA-C
MedStar Washington Hospital Center
Washington, DC, USA
Armando Sardi, MD, FACS
Mercy Medical Center
Baltimore, MD, USA
Garrett M. Nash, MD, MPH
Memorial Sloan Kettering Cancer Center
New York, NY, USA
John D. Spiliotis, MD, PhD
Metaxa Cancer Hospital
Pireus, GREECE
Sang-Yoon Park, MD, PhD
National Cancer Center
Goyang, REPUBLIC OF KOREA
Pieter J. Tanis, MD, PhD
Academic Medical Centre
Amsterdam, THE NETHERLANDS
Antonios-Apostolos K. Tentes, MD, PhD
Metropolitan Hospital
Athens, GREECE
5
Wednesday, November 16
6:00 PM
Registration & Welcome Reception
Thursday, November 17
7:00 AM
Registration & Breakfast
8:00 AM
Welcome Remarks
8:15 AM Welcome Comments from Local Dignitary
Paul H. Sugarbaker, MD, FACS, FRCS
Steven A. Rosenberg, MD, PhD
SESSION I: UPDATE ON CLINICAL TRIALS IN COLORECTAL CANCER
Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS
PROACTIVE PROTOCOLS:
8:30 AM
ProphyloCHIP: CRS and HIPEC with Second-Look Surgery
8:40 AM
Diane Goere, MD, PhD
PRODIGE 7: Adjuvant ± HIPEC for Peritoneal Metastases from
Colon Cancer
8:50 AM
COLOPEC: Adjuvant HIPEC for Primary Colon Cancer
9:00 AM
PROMENADE: Prophylactic HIPEC for Primary Colon Cancer
Francois Quenet, MD
Pieter J. Tanis, MD, PhD
Paolo Sammartino, MD, PhD
TREATMENT PROTOCOLS:
9:10 AM ICARuS EPIC FUDR versus HIPEC after Optimal Cytoreductive
Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum
with Isolated Peritoneal Metastasis
Garrett M. Nash, MD, MPH
9:20 AM Surgery and Oxaliplatin or Mitomycin C in Treating Patients
with Tumors of the Appendix 9:30 AM 9:40 AM 9:50 AM
Edward A. Levine, MD
Cytoreduction and Intraperitoneal Chemotherapy versus
Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
Peter H. Cashin, MD, PhD
COMBATAC: Combined Anticancer Treatment of Advanced
Colon Cancer
Pompiliu Piso, MD, PhD
Current Status and Future Prospects for Clinical Trials in
Peritoneal Metastases from Colorectal Cancer
Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: P. Cashin, D. Goere, E. Levine, G. Nash, P. Piso, F. Quenet,
P. Sammartino, P. Tanis
10:30 AMBreak
6
SESSION II: UPDATE ON CLINICAL TRIALS IN OVARIAN CANCER
1:00 PM
11:00 AM
CRS and HIPEC in Recurrent Ovarian Cancer
SESSION III
John D. Spiliotis, MD, PhD
Moderator: David Morris, MD
11:10 AM HIPEC with Carboplatin for Recurrent Ovarian Cancer, Phase II
2:00 PM Dennis S. Chi, MD
11:20 AM CHIPOR CRS with or without HIPEC for Relapsed Ovarian Cancer
Moderators: Luca Ansaloni, MD; Dennis S. Chi, MD
11:30 AM Jean-Marc Classe, MD, PhD
CHORINE CRS with or without HIPEC Upfront for Primary
Ovarian Cancer
11:40 AM HORSE CRS with or without HIPEC in Ovarian Cancer Recurrence
11:50 AM 12:00 PM 12:10 PM
Luca Ansaloni, MD
2:30 PM
Lunch & Visit the Posters and Exhibits
Keynote Lecture (1): Animal Models: What Can They Tell Us
about the Management of Peritoneal Metastases
Ignace H. de Hingh, MD, PhD
Debate (1): Adjuvant HIPEC is Superior to Second-look
Surgery with HIPEC in High Risk Primary Colorectal Cancer for
Peritoneal Metastases
3:00 PM
Presentation of Best Abstracts (1-4)
Paolo Sammartino, MD, PhD (Pro) vs. Diane Goere, MD, PhD (Con)
Anna Fagotti, MD, PhD
4:00 PMBreak
Secondary Debulking Surgery ± Hyperthermic Intraperitoneal
Chemotherapy in Stage III Ovarian Cancer
SESSION IV
Willemien van Driel, MD, PhD
Outcomes in CRS/HIPEC as Initial Treatment of Ovarian,
Fallopian Tube, and Primary Peritoneal Cancer
Armando Sardi, MD, FACS
HIPEC in Primary Ovarian Cancer, NCC Korea
Moderator: Diane Goere, MD, PhD
4:30 PM
5:00 PM
Debate (2): CRS and HIPEC is the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases
Wim Ceelen, MD, PhD (Pro) vs. David P. Ryan, MD (Con)
Case Presentations (1): Prevention and Treatment of Peritoneal
Metastases from Colorectal Cancer
Sang-Yoon Park, MD, PhD
12:20 PM
Gynecologic Oncology Group 252, IP Carboplatin versus
IP Cisplatin
Current Status and Future Prospects for Clinical Trials in
Ovarian Cancer
NETWORKING WELCOME RECEPTION
6:00 PM
12:30 PM Moderators: Dario Baratti, MD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: D. Bartlett, S. Gonzalez-Moreno, M. Pocard, D. Ryan, V. Verwaal
John K. Chan, MD
Moderators: Luca Ansaloni, MD and Dennis S. Chi, MD
Panelists: J. Chan, D. Chi, J. Classe; A. Fagotti, S. Park, A. Sardi, J. Spiliotis, W. van Driel
7
Meet the Professor Breakfast Sessions
On Friday November 18th and Saturday November 19th, 2016, the 10th International Congress on Peritoneal Surface Malignancies will host (10) morning sessions
that will also include a continental breakfast. Each session will highlight a specific topic in a small group setting with internationally renowned leaders in the field. The
breakout sessions are listed below. Space is limited; please make sure to select one breakout session per day in your registration to confirm participation.
friday, november 18, 2016 | 6:30 am – 8:00 am
1. Drugs, Doses, and Duration of Treatments to Standardize HIPEC and
EPIC for Colorectal, Appendiceal, Gastric, Ovarian, and Peritoneal
Mesothelioma
Wim Ceelen, MD, PhD; Eelco de Bree, MD, PhD; Kurt Van der Speeten, MD, PhD
2. Molecular Assessment in the Management of Peritoneal Metastases
Nita Ahuja, MD; H. Richard Alexander Jr., MD; Edward A. Levine, MD
3. Proactive Management of Colorectal and other Cancers using Adjuvant
HIPEC or Second-Look Surgery
Tom Cecil, BM, DM; Diane Goere, MD, PhD; Charles Honore, MD, PhD ;
Gabriel Liberale, MD; David Morris, MD; Pieter J. Tanis, MD, PhD
4. Starting a New Peritoneal Surface Oncology Program
Dario Baratti, MD; Dennis S. Chi, MD; Beate S. Rau, MD, PhD; Vic Verwaal, MD
5. NIPS and Surgery for Gastric Cancer
Joji Kitayama, MD; Francois Quenet, MD; Yutaka Yonemura, MD, PhD
6. ESSO/PSOGI Certificate in Peritoneal Surface Oncology
7. Unusual Diseases are Treated by CRS and HIPEC: How to Select
Patients who will Benefit
Luca Ansaloni, MD; Lana Bijelic, MD, Marybeth S. Hughes, MD, FACS;
Paul H. Sugarbaker, MD, FACS, FRCS
8. Neoadjuvant, Adjuvant and Long-term IP/IV Chemotherapy, HIPEC,
EPIC for Ovarian Cancer
Naoual Bakrin, MD, PhD; Jean-Marc Classe, MD, PhD; Anna Fagotti, MD, PhD;
Evgenia A. Halkia, MD; Sang-Yoon Park, MD, PhD; Willemien van Driel, MD, PhD;
Stephanie L. Wethington, MD
9. Pseudomyxoma Peritonei: Natural History and Treatment
Yan Li, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI
10. Nurses, APCs and Allied Healthcare Professionals: Patient’s Journey
with Peritoneal Malignancy – Part 1
Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Laura A. Lambert, MD;
Samantha A. Moritz, PA
Marcello Deraco, MD; Santiago Gonzalez-Moreno, MD, PhD
Underline = Session Chairperson
8
saturday, november 19, 2016 | 6:30 am – 8:00 am
11. Global Guidelines for Management of Peritoneal Mesothelioma
H. Richard Alexander Jr., MD; Marcello Deraco, MD; Kiran K. Turaga, MD, MPH
12. Pseudomyxoma Peritonei: Follow-up and Management of Recurrent Disease
Tom Cecil, BM, DM; Nader N. Hanna, MD; John D. Spiliotis, MD, PhD
13. Intraperitoneal Ports: When, Where, Why, How, Always or Never?
Lana Bijelic, MD; John K. Chan, MD; Sang-Yoon Park, MD, PhD
14. Peritoneal Metastases from Small Bowel Adenocarcinoma:
Results of Treatment
Eelco de Bree, MD, PhD; Ignace H. de Hingh, MD, PhD; Yutaka Yonemura, MD, PhD
15. Surgical Complications and Return to the OR
Richard A. Hoefer Jr., DO; Pompiliu Piso, MD, PhD; Vic Verwaal, MD
16. Laparoscopy and Peritoneal Surface Malignancy
Jesus Esquivel, MD; Olivier Glehen, MD, PhD; Gabriel Liberale, MD;
Marc Pocard, MD, PhD; Kurt Van der Speeten, MD, PhD
17. Peritoneal Metastases and Liver Metastases
David L. Bartlett, MD; Joel M. Baumgartner, MD, MAS, FACS; Diane Goere, MD, PhD
18. Balancing the Books for CRS and HIPEC in a Diminishing Economy,
a Global Exploration
Wim Ceelen, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI; Garrett M. Nash, MD, MPH
19. Consensus Regarding Concerning Radiologic Features Used to Select
Patients for CRS and HIPEC
Gina Brown, MD, FRCR; Clarisse Dromain, MD, PhD; James S. Jelinek, MD;
Armando Sardi, MD, FACS; Paul H. Sugarbaker, MD, FACS, FRCS
20. Nurses, APCs and Allied Healthcare Professionals: Patient’s Journey with
Peritoneal Malignancy – Part 2
Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Faheez Mohamed, MD; Samantha A. Moritz, PA
Underline = Session Chairperson
Call for Abstracts
The 10th International Congress on Peritoneal Surface Malignancies
(PSOGI 2016) aims at improving the knowledge, treatment and outcome
regarding peritoneal surface malignancies. The Scientific Organizing
Committee requests participants to submit an abstract to present at the
PSOGI 2016 conference. In order to promote multidisciplinary discussions
during the conference, all involved disciplines such as surgery, radiology,
medical oncology, pathology, and pharmacology are encouraged to
submit abstracts to the program. PSOGI 2016 intends to create sufficient
room for papers and posters to be presented. Selected abstracts will be
incorporated into the plenary sessions for oral presentation.
recognition
Selected authors will be asked to provide an abstract poster at the
meeting, November 17-19, 2016. All abstracts will be published in the
official PSOGI 2016 program book.
submission details
•
Abstracts must be submitted electronically at www.psogi2016.com
by August 1, 2016.
•
All abstract submitters will be notified of acceptance status no later
than September 2, 2016.
•
If you have any questions, please call 202- 780-1655 or send an
email to [email protected].
For categories and information regarding rules and regulations,
please visit www.psogi2016.com.
9
Friday, November 18
SESSION V: MEET THE PROFESSOR BREAKFAST SESSIONS
6:30 AM
Registration and Meet the Professor Breakfast Sessions
(See page 8 for more Information)
SESSION VI: UPDATE ON CLINICAL TRIALS IN GASTRIC CANCER
Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD
8:15 AM
8:30 AM
8:40 AM
8:50 AM
Opening Comments and Presentation of the Events of the Day
Paul H. Sugarbaker, MD, FACS, FRCS
GastriCHIP Gastrectomy ± HIPEC as Adjuvant for Primary
Gastric Cancer
Olivier Glehen, MD, PhD
NIPOX Adjuvant Intraperitoneal Oxaliplatin for Gastric Cancer
with Peritoneal Metastases
Francois Quenet, MD
GASTRIPEC Cytoreductive Surgery (CRS) with/without HIPEC in
Gastric Cancer with Peritoneal Carcinomatosis
SESSION VII: UPDATE ON INTERNATIONAL PERITONEAL METASTASES REGISTRIES
Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH
9:30 AM International Registry on Peritoneal Mesothelioma
9:40 AM
Big RENAPE including Rare Diseases Treated with CRS and HIPEC
9:50 AM German Registry
10:00 AM Dutch Registry
Shigeki Kusamura, MD, PhD
Diane Goere, MD, PhD
Pompiliu Piso, MD, PhD
Vic Verwaal, MD
10:10 AM Current Status and Future Prospects for Peritoneal Metastases
Registries
Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH
Panelists: J. Esquivel, D. Goere, S. Kusamura, M. Pocard, V. Verwaal
10:30 AMBreak
Beate S. Rau, MD, PhD
9:00 AM
Phoenix GC Neoadjuvant Intraperitoneal and Systemic
Chemotherapy (NIPS) for Gastric Cancer with Peritoneal
Metastases
Joji Kitayama, MD
9:10 AM
Current Status and Future Prospects for Clinical Trials in
Gastric Cancer
Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD
Panelists: O. Glehen, J. Kitayama, F. Quenet, P. Sugarbaker
10
SESSION VIII
SESSION X
11:00 AM
Presentation of Best Abstracts (5-8)
4:30 PM
12:00 PM
Case Presentations (2): Peritoneal Metastases from Gastric Cancer
Moderator: Beate S. Rau, MD, PhD
Yutaka Yonemura, MD, PhD
Moderators: Beate S. Rau, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: O. Glehen, N. Hanna, J. Kitayama, Y. Yonemura
1:00 PM
Lunch & Visit the Posters and Exhibits
Moderator: Yan Li, MD, PhD
5:00 PM
SESSION IX
5:30 PM
2:00 PM
Moderator: Yutaka Yonemura, MD, PhD
2:30 PM
Keynote Lecture (2): Current Treatment Options for
Management of Gastric Cancer with Peritoneal Metastases
Joji Kitayama, MD
Debate (3): Recurrent Ovarian Cancer: CRS and HIPEC is a
Reasonable Treatment Option Now in Selected Patients
3:00 PM
Case Presentations (3): CRS and HIPEC for Unusual Diseases
Naoual Bakrin, MD, PhD (Pro) vs. Stephanie L. Wethington, MD (Con)
Moderators: Paul H. Sugarbaker, MD, FACS, FRCS; Vic Verwaal, MD
Panelists: D. Bartlett, E. de Bree, M. Deraco, D. Goere, A. Tentes
4:00 PMBreak
6:30 PM
Keynote Lecture (3): Progress in the Management of Primary
and Recurrent Ovarian Cancer in Cordoba, Spain
Alvaro Arjona-Sanchez, MD, PhD
Debate (4): Pharmacology and Clinical Data Show that
Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current
Standard of Care for Peritoneal Metastases from Colon Cancer
Joel M. Baumgartner, MD, MAS, FACS (Pro) vs. Olivier Glehen, MD, PhD (Con)
Case Presentations (4): The Prevention and Treatment of
Peritoneal Metastases from Ovarian Cancer
Moderators: Anna Fagotti, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: L. Ansaloni, D. Chi, J. Spiliotis, W. van Driel, S. Wethington
Closing Remarks
Paul H. Sugarbaker, MD, FACS, FRCS
CONGRESS BANQUET WITH HISTORICAL VIDEO | 7:30 PM
Comments by Francois-Noel Gilly, MD, PhD and Frans A.N. Zoetmulder, MD, PhD
Presentation of Certificates for European School of
Peritoneal Surface Oncology
11
Saturday, November 19
SESSION XI: MEET THE PROFESSOR BREAKFAST SESSIONS
6:30 AM
Registration and Meet the Professor Breakfast Sessions
(See page 9 for more Information)
SESSION XIII: THE FUTURE IS NOW*
Moderator: H. Richard Alexander Jr., MD
11:00 AM
SESSION XII: NEW TECHNOLOGIES TO OPTIMIZE MANAGEMENT OF
PERITONEAL SURFACE MALIGNANCY*
Moderator: David L. Bartlett, MD
8:15 AM
Opening Comments and Presentation of the Events of the Day
8:30 AM Keynote Lecture (4): Genomic Medicine as it Involves
Peritoneal Metastases
Paul H. Sugarbaker, MD, FACS, FRCS
Nita Ahuja, MD
9:00 AM
Preoperative Assessments
9:20 AM
Pressurized Intraperitoneal Chemotherapy (PIPAC)
9:30 AM
Multi-Detector CT to Identify Poor Prognostic Factors in Primary Colorectal Cancer
Jesus Esquivel, MD
Marc Pocard, MD, PhD
11:30 AM
12:30 PM
Keynote Lecture (6): 90% of the Adverse Outcomes Occur in
10% of Patients. Can We Identify the High Risk Groups?
Charles Honore, MD, PhD
Case Presentations (5): Prevention and Treatment of Peritoneal
Metastases from Appendiceal Cancer
Moderators: H. Richard Alexander Jr., MD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: D. Bartlett, S. Gonzalez-Moreno, B. Moran, D. Morris, P. Tanis
10 Take Home Messages
Santiago Gonzalez-Moreno, MD, PhD
12:45 PM
Closing Remarks and Looking Ahead to PSOGI Congress 2018
in Paris
Olivier Glehen; MD, PhD, Diane Goere, MD, PhD; Marc Pocard, MD, PhD;
Paul H. Sugarbaker, MD, FACS, FRCS
1:00 PMAdjourn
Gina Brown, MD, FRCR
10:00 AM
Keynote Lecture (5): Bidirectional Adjuvant Normothermic Chemotherapy (BANC) Long-Term for Management of Ovarian
Cancer
John K. Chan, MD
10:30 AMBreak
* In collaboration with the Society of Surgical Oncology
12
Saturday Post-Conference Satellite Symposia
SATELLITE SYMPOSIUM (OPTION 1)
Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC
This satellite symposium will describe the pharmacodynamics and pharmacokinetics of chemotherapy administered with heat in the operating room. Additionally, novel approaches to
intraoperative and long-term combined intraperitoneal and systemic chemotherapy will be investigated. Exploration of ovarian cancer molecular agents for intraperitoneal administration will
also take place. The program will include ample time for questions and faculty will provide key recommendations for a standardized chemotherapy regimens for peritoneal metastases.
SESSION I
SESSION II
1:30 PM
Pharmacodynamics of Intraperitoneal Chemotherapy
4:30 PM Pharmacokinetics of Chemotherapy Delivery by PIPAC
5:00 PM Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD
2:00 PM 2:30 PM Wim Ceelen, MD, PhD
Marc Pocard, MD, PhD
Moderator: David Morris, MD; Marc Pocard, MD, PhD
Pharmacology of Intraperitoneal Chemotherapy for Ovarian Cancer David S. Alberts, MD
Molecular Agents for Intraperitoneal Administration
Olivier Glehen, MD, PhD
David Morris, MD
Novel Approaches to Intraperitoneal Drug Delivery
5:30 PM Joji Kitayama, MD
3:00 PM Long-Term IP/IV Chemotherapy for Ovarian Cancer:
Rationale and Pharmacology
6:00 PM Knowing What We Know Now, the Optimal Perioperative
Chemotherapy Regimens are…
Questions & Discussion
6:30 PM 3:30 PM John K. Chan, MD
Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD
Panelists: W. Ceelen, J. Chan, D. Morris, M. Pocard
4:00 PM Break
Nanomicellar Drugs for Intraperitoneal Administration
Kurt Van der Speeten, MD, PhD
Questions & Discussion
Moderator: David Morris, MD; Marc Pocard, MD, PhD
Panelists: D. Alberts, O. Glehen, J. Kitayama, K. Van der Speeten
7:00 PM Adjourn
13
Saturday Post-Conference Satellite Symposia
SATELLITE SYMPOSIUM (OPTION 2)
Peritoneal Metastases Imaging
Through a collaboration of an international planning team to standardize the technology and terminology for imaging peritoneal metastases, this symposium will explore the clinical utility of
radiologic studies to select patients who will benefit from the surgical treatment of peritoneal metastases.
SESSION I
SESSION II
1:30 PM
4:30 PM
Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
An Initial Attempt to Standardize a Best Technology of CT, MRI,
PET for Peritoneal Metastases
2:00 PM
Formulating a Lexicon of Concerning Radiologic Features
2:30 PM
Clarisse Dromain, MD, PhD
James S. Jelinek, MD
Description of Peritoneal Metastases by CT
Gina Brown, MD, FRCR
3:00 PM
Description of Peritoneal Metastases by MRI
3:30 PM
Pascal Rousset, MD, PhD
Questions & Discussion
Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
Panelists: G. Brown, P. Rousset
4:00 PMBreak
Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
Optical Imaging for Detection of Peritoneal Metastases
Gabriel Liberale, MD
5:00 PM
Using Radiology to Define High Risk for Peritoneal Metastases
in Primary Gastrointestinal Cancer, Colon, Gastric, and Pancreas
5:35 PM
6:00 PM
6:30 PM
Gina Brown, MD, FRCR
Peritoneal Metastases: Their Associated Clinical FeaturesCan PET be of Help?
Clarisse Dromain, MD, PhD
Is There a Minimal Required Report for Peritoneal Metastases?
Pascal Rousset, MD, PhD
Questions & Discussion
Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
Panelists: G. Brown, G. Liberale, P. Rousset
7:00 PMAdjourn
14
Registration Information
registration fees
cancellation policy
NOW through September 1, 2016
$500
Physician
$350
Residents/Fellow
$350
Advanced Practice Clinician
$350Nurse
$350
Allied Health Professional
Cancellations made in writing by Friday, September 30, 2016 will be subject to a
50% penalty. No refunds will be given after September 30, 2016. Cancellations
will not be accepted by telephone. In the unlikely event that the course is
canceled, MedStar Health will refund the registration fee, but is not responsible
for any travel costs.
September 2 through November 15, 2016*
$700
Physician
$550
Residents/Fellow
$550
Advanced Practice Clinician
$550
Nurse
$550
Allied Health Professional
*An additional $100 will be added to onsite registrations November 16-19
Post-Conference Satellite Symposia (Additional Fee)
$150
Physician
$100
Residents/Fellow
$100
Advanced Practice Clinician
$100
Allied Health Professional
Please visit our secure website at www.psogi2016.com to register to attend.
We are unable to accept registrations or cancellations by telephone.
All registrations will be confirmed by email only. Please use an email address
that you check regularly. If you have questions regarding registration or do not
receive an email confirmation of your registration within 1-2 business days,
please contact us at [email protected] or 202-780-1655.
Please call 202-780-1655 or email [email protected] if you any questions
or need any additional information.
venue information
Omni Shoreham Hotel
2500 Calvert Street, NW, Washington, DC 20008
202-234-0700
room block
Room Block Rate: $239 night plus applicable tax, single or double occupancy
Please call Omni Reservations at 1-800-THE-OMNI (1-800-843-6664) to book your
room today! Reservations can also be made online by visiting psogi2016. When
making reservations by phone, please indicate that you are a part of the “10th
International Congress on Peritoneal Surface Malignancies Group.”
Our preferred discount room block is available Monday, November 14th, 2016
through Tuesday, November 22nd, 2016. Reservation requests received after that
date will be based on availabilty at the hotel's prevailing rates.
The cut-off date for making reservations is Friday, October 21, 2016.
15
10 International Congress on
Peritoneal Surface Malignancies
th
November 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC
Course Director:
Paul H. Sugarbaker, MD, FACS, FRCS
MedStar Washington Hospital Center
Washington, DC
www.psogi2016.com
3007 Tilden Street, NW, Suite 3N
Washington, DC 20008
NON-PROFIT ORG.
U.S. POSTAGE
PAID
MEDSTAR
WASHINGTON
HOSPITAL
CENTER